Syndax Pharmaceuticals (SNDX) Non Operating Income (2015 - 2026)

Syndax Pharmaceuticals' Non Operating Income history runs 12 years deep, the most recent figure standing at -$8.5 million for Q1 2026.

• In Q1 2026, Non Operating Income fell 677.87% year-over-year to -$8.5 million; the TTM figure through Mar 2026 stood at -$19.7 million (down 255.14% YoY), while the FY2025 annual figure was -$12.3 million, down 158.99% from the prior year.
• Non Operating Income for Q1 2026 stood at -$8.5 million, down from -$5.5 million in the prior quarter.
• The five-year high for Non Operating Income was $7.1 million in Q1 2024, with the low at -$8.5 million in Q1 2026.
• The 5-year median for Non Operating Income is $2.2 million (2024), against an average of $1.4 million.
• The sharpest annual moves came in 2023 and 2026: Non Operating Income soared 3230.92% in 2023, then sank 677.87% in 2026.
• Syndax Pharmaceuticals' Non Operating Income stood at $2.8 million in 2022, then soared by 91.33% to $5.4 million in 2023, then sank by 59.57% to $2.2 million in 2024, then plunged by 348.91% to -$5.5 million in 2025, then tumbled by 54.98% to -$8.5 million in 2026.
• Business Quant data shows SNDX's Non Operating Income at -$8.5 million in Q1 2026, -$5.5 million in Q4 2025, and -$3.3 million in Q3 2025.